ALLO-647

ALLO-647 is a monoclonal antibody developed by Allogene Therapeutics. Its target is CD52 (the sponsor names CD52). The sponsor states: Monoclonal antibody that recognises the CD52 antigen; used as part of a lymphodepletion regimen (with fludarabine and cyclophosphamide) ahead of allogeneic CAR T-cell dosing. ClinicalTrials.gov describes the intervention as: ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in diffuse large B-cell lymphoma. The largest, NCT04416984, plans to enrol 160 participants with primary completion expected 2029-02. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.